Vect-Horus

Executive Summary

Vect-Horus is a French biotechnology company pioneering proprietary vector-based technologies for targeted drug delivery across biological barriers, with a primary focus on the blood-brain barrier (BBB). Founded in 2005 and headquartered in Marseille, the company operates as a platform technology provider, licensing its Vect-Horus delivery system to pharmaceutical partners to enable CNS penetration of therapies that otherwise cannot cross the BBB. This approach addresses a critical bottleneck in neuroscience drug development, potentially unlocking treatments for Alzheimer’s, Parkinson’s, and brain cancers. Despite being a private, pre-commercial entity, Vect-Horus has established multiple collaborations, generating revenue through partnerships and milestone payments. With a validated platform and growing interest in CNS drug delivery, Vect-Horus is well-positioned to expand its partnership network and advance its own pipeline. The company’s technology has demonstrated proof-of-concept in preclinical models, and it continues to optimize its vectors for diverse therapeutic modalities, including small molecules, peptides, and antibodies. Key near-term catalysts include securing additional pharmaceutical alliances, progressing lead programs toward the clinic, and raising capital to support R&D. While the competitive landscape includes other BBB delivery platforms, Vect-Horus’s unique vector design and decade-plus experience provide a distinct advantage. Given the high unmet need in CNS diseases, the company represents a compelling opportunity for investors seeking exposure to innovative drug delivery technologies.

Upcoming Catalysts (preview)

• Q3 2026New Pharmaceutical Partnership for CNS Delivery55% success
• 2027First Clinical Trial Application for a Lead Program40% success
• 2026Series B Financing Round to Support Platform Expansion60% success